Connect with us

Menopause

Testosterone patch shows promise for menopausal women

Published

on

A new testosterone patch has shown positive results in initial Phase 1 clinical testing, offering renewed hope for women seeking hormone therapy.

Drug delivery firm Medherant has announced encouraging findings from its Phase 1 trial of the TEPI Patch, carried out at Hammersmith Medicines Research (HMR) in London.

The study found that the patch effectively delivers testosterone through the skin, restoring blood levels to the normal pre-menopausal range.

The development could help address a major gap in treatment options for women going through menopause.

Karolina Afors is medical director of Medherant – the company that developed the patch.

She said: “These latest results represent another major step in the development of the testosterone TEPI Patch to address a significant condition faced by many post-menopausal women.

“Our patch technology will provide women with a superior and convenient treatment option for testosterone as part of menopause hormone therapy.”

Medherant, a clinical-stage spin-out from the University of Warwick, has developed what it says could become the first-in-class testosterone patch designed specifically for women.

Built on its proprietary TEPI Patch technology, it provides strong adhesion, ensuring reliable and comfortable wear throughout daily activities.

The company has secured approval from both the Medicines and Healthcare products Regulatory Agency (MHRA) and the Research Ethics Committee for its clinical trial application to begin the next multiple-dose pharmacokinetic study – a follow-up study testing repeated doses – due to start dosing later this year.

This study focuses on advancing the TEPI Patch as a potential treatment for HSDD.

Medherant has also obtained scientific advice from the MHRA and the Swedish Medical Products Agency to inform its regulatory strategy for product registration in the UK and EU.

David Haddleton is chief scientific officer at Medherant and professor in the Department of Chemistry at the University of Warwick.

He said: “The success of this initial trial paves the way for our upcoming multiple-dose study which starts dosing before the end of the year.

“We remain committed to accelerating development to bring the testosterone TEPI Patch to market swiftly and to deliver the adhesion and comfort that women deserve.”

Despite recommendations in the NICE Menopause Guidelines and the Global Consensus Position Statement on the Use of Testosterone Therapy for Women, there is currently no approved testosterone patch product for women.

Transdermal delivery offers advantages over oral hormone administration by avoiding peaks in drug levels that can lead to side effects, and by allowing better dose control than gels and creams.

Alongside developing its own products, Medherant collaborates with pharmaceutical partners on other transdermal projects.

In March 2024, it announced a development collaboration agreement with Bayer to create a patch product for an already-approved oral medicine.

Menopause

Menopause care failing women worldwide, review finds

Published

on

Menopause care remains fragmented and unequal worldwide, leaving many women without evidence-based support, a major review has found.

The review identified significant gaps in care despite menopause affecting millions of people around the world.

Drawing on 89 studies from several countries and diverse populations, it found that many women experience fragmented services, limited access to evidence-based treatment and inadequate support from healthcare providers.

Women often reported feeling dismissed, unsupported and uninformed about menopause and the treatments available.

The review also found persistent inequalities in access to menopause support.

Race, socioeconomic status, cultural background and geography often shaped the barriers women faced when seeking care.

Researchers found that healthcare professionals often receive insufficient training on menopause.

National clinical guidelines were also applied inconsistently, while culturally responsive care remained limited.

These gaps were particularly evident among marginalised groups, including LGBTQ+ people, Indigenous communities, migrant women and those experiencing surgical menopause.

The review found that telehealth could improve access to menopause care, although the authors said it was not a universal solution.

They said its acceptability and suitability varied across different populations and settings.

The review called for better education and training for healthcare providers, clearer roles and responsibilities across health services and patient-centred, culturally competent models of care.

It also highlighted the need for a greater focus on equity to ensure everyone can access high-quality menopause support.

The findings were based on a review of 4,056 published records, with 89 studies meeting the inclusion criteria.

Most of the evidence came from the UK, US and Australia and included qualitative, quantitative, mixed-methods and intervention studies.

Continue Reading

News

Disadvantaged neighbourhoods linked to faster heart health decline in midlife women, research shows

Published

on

Women in disadvantaged areas may face poorer heart health and faster decline as they approach menopause, new research suggests.

Researchers followed 1,200 women in eastern Massachusetts for more than 20 years, from pregnancy into midlife.

The study measured heart health at five points using a score based on eight health and lifestyle factors, including blood pressure, cholesterol, sleep, diet and physical activity.

Women living in the most socially vulnerable neighbourhoods scored about six to 10 points lower on heart health across more than two decades of follow-up than those in the least disadvantaged neighbourhoods.

The differences were already clear three years after enrolment and continued into midlife.

Researchers also found that women in these neighbourhoods had faster declines before menopause, the stage when periods stop and cardiovascular risk can rise. Cardiovascular health means the health of the heart and blood vessels.

Socioeconomic factors also appeared to shape outcomes. Women with lower income, less education, or who identified as non-Hispanic Black had lower heart health scores throughout the study.

The findings highlight how long-term exposure to social and environmental conditions may affect cardiovascular risk over time.

Even modest differences in heart health scores may matter, as previous research has linked small decreases in these scores with higher risks of cardiovascular disease and death.

Senior author Izzuddin Aris, associate professor at Harvard Medical School and the Harvard Pilgrim Health Care Institute, said: “Our study shows that heart health in midlife is shaped by more than personal choices. Income, education, and neighbourhood conditions may all play a role.”

Neighbourhood conditions continued to affect heart health even after researchers took income and education into account.

Women who lived for years in highly vulnerable neighbourhoods had persistently lower scores and poorer cardiovascular health trajectories.

Aris added: “The years before and around menopause may be an important time to support women’s heart health.

“This is especially true for women living in under-resourced neighbourhoods.”

The findings suggest prevention efforts could include better access to healthy food, safe places to be active and quality healthcare, particularly for women seeking to protect their heart health over time.

The study used data from Project Viva, a long-term research study that has followed women since pregnancy in the early 2000s through midlife.

Researchers collected repeated health data over more than two decades, allowing them to track long-term patterns in heart health.

Continue Reading

Menopause

Many women still confused about perimenopause, research finds

Published

on

One in three US women older than 35 are no sure whether they are in perimenopause, new research has revealed.

The findings suggest uncertainty remains common, largely because of knowledge gaps, symptom confusion and difficulty getting confirmation or care.

Perimenopause is the transitional stage before a woman’s final period, when hormone levels fluctuate and symptoms can change over time.

It usually begins in the mid-40s, although timing varies widely, and can last for around four to eight years.

Symptoms can include hot flushes, psychological symptoms and urogenital symptoms, which affect the urinary and genital areas.

Dr Stephanie Faubion, medical director for The Menopause Society and one of the study authors, said: “This large study showed that one in three US women aged older than 35 years are not sure whether they are in perimenopause.

“Further, the study highlights that symptom confusion, misconceptions, and barriers to care are leaving many women without the clarity and support they need during the menopause transition.

“Recognising perimenopause uncertainty as a common experience can help shift the conversation from searching for a diagnosis to providing women with the information, validation, and support they need to navigate this natural life transition with confidence.”

More than 7,600 US women aged 35 and older took part in the study, which looked at how common uncertainty around perimenopause is and what may be driving it.

Overall, 34 per cent of participants said they were unsure of their reproductive stage.

Uncertainty varied by age and symptom burden, reaching 42 per cent among women aged 40 to 44 and 37 per cent among those with severe symptoms.

Symptom confusion was the most common factor, cited in 56 per cent of responses.

This included difficulty making sense of bodily changes and telling perimenopause apart from other possible causes, such as premenstrual syndrome, thyroid disease or mental health conditions.

Knowledge gaps and information-seeking made up 28 per cent of responses, reflecting limited awareness, age-based assumptions and attempts to find reliable information.

Barriers to confirmation and care made up 16 per cent, including dismissive healthcare encounters and reluctance to acknowledge perimenopause.

Younger women aged 35 to 39 were more likely to cite knowledge gaps, while healthcare barriers were most common among women aged 40 to 44.

The researchers said clinicians should take a more flexible approach to recognising the emotional, cognitive and physical symptoms that can occur during perimenopause.

They said healthcare professionals should not rely too heavily on irregular periods as the main sign, because some women have symptoms before major cycle changes.

 

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.